Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$29.13M$29.13Mderived+37.4% vs Q4 2023 Net Income$7.18M$7.18Mderived+6,197.4% vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$18,197,000+40.7% Operating Incomederived$7,111,000N/M Operating Cash Flowderived$8,583,000+1,222.5% Margins · derivedGross margin62.5%+1.4 pt vs Q4 2023
Operating margin24.4%+25.2 pt vs Q4 2023
Net margin24.6%+24.1 pt vs Q4 2023
ended Dec 31, 2024 · filed Mar 4, 2025 · 63 d after period end